High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Japan Society for Hematopoietic Cell Transplantation....

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2020-02, Vol.111 (2), p.256-266
Main Authors: Kim, Sung-Won, Asakura, Yoshitaka, Tajima, Kinuko, Iwai, Toshiki, Taji, Hirofumi, Chou, Takaaki, Morishima, Yasuo, Suzumiya, Junji, Sakamaki, Hisashi, Suzuki, Ritsuro, Fukuda, Takahiro
Format: Article
Language:English
Subjects:
Autografts
B-cell lymphoma
Immunotherapy
Lymphocytes B
Lymphoma
Monoclonal antibodies
Polls & surveys
Remission
Risk
Rituximab
Stem cell transplantation
Stem cells
Survival
Targeted cancer therapy
Therapy
Transplantation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Of the 1222 patients in the database, 576 (47%) received ASCT in first complete remission (CR1), 140 (12%) in first partial remission, 281 (23%) in sensitive relapse, 150 (12%) in resistant or sensitivity-unknown relapse, and 75 (6%) in primary refractory status. With a median follow-up of 22 months, the 2-year overall survival (OS) and progression-free survival rates were 71% and 68%, respectively. The cumulative incidences of 2-year non-relapse mortality and relapse/progression were 6% and 26%, respectively. Relapse/progression after ASCT in the rituximab era (2002-2007) was significantly lower than that in the pre-rituximab era (1990-2001; P 
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-019-02772-1